StockWatch
·

Inhibrx Biosciences, Inc. Q3 FY26 Results

INBXQ3 FY26 Results
Filing
MetricValue ($ M)
Revenue2.00
Total Income2.00
Expenditure33.74
PBT-38.73
Net Profit-38.73
OPM—
NPM—
EPS-2.46
View full financials

Inhibrx Biosciences Reports Q3 2026 Financial Results

14 Nov 2026 · 14 Nov, 2:44 am

Summary

Inhibrx Biosciences reported its financial results for the third quarter of 2026, recognizing $2.0 million in revenue from a license agreement with Pfizer, compared to no revenue in the prior year quarter. Research and development expenses decreased to $26.0 million, while general and administrative expenses rose to $7.8 million due to pre-commercialization activities. The company reported a net loss of $38.7 million, or $2.46 per share, an increase from the $35.3 million net loss in Q3 2025. As of September 30, 2026, Inhibrx held $199.5 million in cash and cash equivalents.

Key Highlights

  1. 1

    Inhibrx Biosciences recognized $2.0 million of revenue during the third quarter of 2026 under a license agreement with Pfizer, Inc.

  2. 2

    The Company did not recognize any revenue during the third quarter of 2025.

  3. 3

    Research and development expenses were $26.0 million for the third quarter of 2026, a decrease from $28.5 million in the prior year period.

  4. 4

    General and administrative expenses increased to $7.8 million during the third quarter of 2026, compared to $5.3 million during the third quarter of 2025.

  5. 5

    Total other expense increased to $7.0 million during the third quarter of 2026, primarily due to higher interest expense on the Company’s outstanding loan balance.

  6. 6

    Net loss was $38.7 million during the third quarter of 2026, or $2.46 per share, basic and diluted, compared to a net loss of $35.3 million, or $2.28 per share, in the prior year period.

  7. 7

    As of September 30, 2026, the Company had cash and cash equivalents of $199.5 million.

Informational and educational content only. Not investment advice.